Moleculin Biotech, Inc. — Q3 2017 Form 10-Q
Business context and period: Clinical-stage oncology drug developer; quarter ended September 30, 2017. The company had four candidates across three approaches: Annamycin, WP1066, WP1220 and WP1122. It had no product revenue and relied on external financing.
Financial performance and liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.061 million | $0.497 million | $2.260 million | $0.616 million |
| General and administrative | $1.338 million | $0.924 million | $2.987 million | $1.848 million |
| Operating loss | $2.404 million | $1.422 million | $5.260 million | $2.466 million |
| Net loss | $2.866 million | $1.432 million | $6.620 million | $2.503 million |
| Basic and diluted loss per share | $0.14 | $0.12 | $0.37 | $0.28 |
| Net cash used in operations | Not stated for quarter | Not stated for quarter | $4.934 million | $2.596 million |
As of September 30, cash and cash equivalents were $8.736 million, versus $5.007 million at December 31, 2016. Current assets were $9.463 million and current liabilities $1.832 million. Total assets were $20.633 million; total liabilities were $1.982 million. Convertible notes were fully converted into common stock in June 2017; no notes remained outstanding at quarter-end. A $743,000 current warrant liability remained. No profit margin is meaningful because the company had no revenue.
Nine-month financing cash flow was $8.675 million, principally from the February offering, warrant exercises and ATM sales. The company reported 20,822,214 shares outstanding at September 30, 2017; 21,136,059 were outstanding at November 1.
Changes versus prior comparable periods
- Q3 operating expenses rose to $2.404 million from $1.422 million, reflecting higher R&D and G&A spending. Nine-month operating expenses more than doubled, to $5.260 million from $2.466 million.
- Q3 net loss approximately doubled year over year; nine-month net loss increased to $6.620 million from $2.503 million. The 2017 results included substantial non-cash warrant revaluation effects, unlike 2016.
- Operating cash use increased to $4.934 million for the first nine months from $2.596 million. Financing proceeds kept cash above the December 2016 balance.
Outlook, developments and risks
- The FDA allowed the Annamycin IND to proceed in September 2017. A Phase I/II trial for relapsed or refractory AML was planned, with a Polish site and local authorization still subject to regulatory approval. Management said patient treatment might begin as early as late December 2017, depending on authorization; the dose-ranging phase is intended to establish a recommended Phase 2 dose.
- Management stated that September 30 cash, together with cash generated in Q4, was expected to fund planned operations into Q3 2018, subject to clinical enrollment and drug-product use. Separately, the going-concern note says cash was sufficient into, but not beyond, the near term and identifies substantial doubt about the company’s ability to continue as a going concern. Additional financing will be needed; availability and terms are uncertain.
- The company reported FDA Orphan Drug designation for Annamycin. The Annamycin drug substance was no longer patent-protected; planned new patent applications concern formulation, synthesis and reconstitution, with no assurance patents will issue.
- WP1066 and WP1122 remained in development. Activities included preparation for a WP1220 proof-of-concept study in Poland, collaborations and preclinical work, and support for an MD Anderson WP1066 IND filed November 1, 2017. These developments did not establish clinical efficacy.
- Key risks include clinical and regulatory uncertainty, dependence on future financing, reliance on third-party manufacturers and collaborators, and the possibility that intellectual-property protection will not be obtained. The company had no pending legal proceedings.
- Management concluded disclosure controls were not effective because of a material weakness in segregation of accounting duties. A full-time controller was added during the quarter; further staffing was planned. Management reported additional procedures and analysis to support the financial statements.
Investor verification priorities
- Reconcile the going-concern disclosures: management’s stated runway into Q3 2018 versus the note’s “into but not beyond the near term” language and substantial-doubt conclusion.
- Check the Q3 warrant accounting presentation: the statements report a $470,000 loss from change in warrant fair value, while MD&A says Q3 net loss included $0.5 million of non-cash income related to warrant expiration. The filing text does not clearly reconcile these descriptions.
- Track actual Annamycin trial authorization, site activation, enrollment, costs and timing against the conditional forecast; verify the status and results of the WP1066 and WP1220 programs.
- Assess financing needs and dilution, including use of the $13 million ATM facility, subsequent ATM sales, warrant exercises and remaining securities potentially convertible into shares.
- Monitor remediation of the accounting segregation-of-duties material weakness and progress toward new Annamycin patent protection.